A happy Sunday to you, myeloma world.

We hope you have been having a pleasant weekend. We've been looking over some of the new multiple myeloma research published in the past few days, and there are two studies we thought we would discuss with you in today's Myeloma Morning.

The first is a case report involving a myeloma patient who has been in remission for more than 15 years. This remission, it seems, may be an unexpected “side effect” of radiation treatment the patient received.

The second study we'll …

A happy Saturday to you, myeloma world.

We have some good news to report today. It also is im­por­tant news related to Darzalex (dara­tu­mu­mab).

Some addi­tional clin­i­cal trial results related to Darzalex were made public earlier this week, but they have not received much attention.

The new results show that adding Darzalex to Velcade (bor­tez­o­mib) and dexa­metha­sone sub­stan­tially – some might even say dramatically – extends pro­gres­sion-free survival in re­lapsed multiple myeloma patients.

The new results expand on news announced at the end of March, which we covered in …

Good morning, myeloma world.

Things have settled down here at Myeloma Morning Headquarters compared to how they were 36 hours ago. We once again have 21^st century tech­nology doing what it is supposed to be doing. It's wonderful.

Speaking of wonderful, let's talk some more about the multiple myeloma research to be presented at the upcoming 2016 annual meeting of the American Society of Clinical Oncology (ASCO). We discussed the meeting in the previous edition of Myeloma Morning, noting that ASCO has re­leased the titles – but not the abstracts – …

We hope you had a pleasant Wednesday, myeloma world.

Our Wednesday was going full steam ahead until modern tech­nology at Myeloma Morning Headquarters decided to take a vaca­tion. And this had to hap­pen, of course, on a day when we have some particularly in­ter­est­ing devel­op­ments to discuss.

What “developments” might those be, you ask?

Well, those “developments” would be the titles of all pre­sen­ta­tions to be given at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The titles were made public on Wednesday.

In this edition of

A happy Tuesday to you, myeloma world.

We have some in­ter­est­ing re­search to share with you.

First, we have re­­sults of a Phase 2 study investi­gating Empliciti (elotuzu­mab) in com­bi­na­tion with Velcade (bor­tez­o­mib) and dexa­metha­sone (Decadron) in re­lapsed and re­frac­tory myeloma patients. The re­­sults show that Empliciti plus Velcade and dexa­metha­sone im­proves pro­gres­sion-free sur­vival com­pared to Velcade and dexa­metha­sone alone, without adding any sig­nif­i­cant side effects.

We also report on a study out of Italy that explores using Treanda (benda­mustine) in addi­tion to mel­phalan (Alkeran) as the high-dose chemo­therapy …

Good day, myeloma world.

Monday's tend to be quiet here at Myeloma Morning Headquarters – at least when it comes to new research that needs to be reviewed and summarized. Today is no exception. There was no new myeloma-related research when we checked this morning, and just one or two news items.

We do have a few things, however, that we'd like to review with you.

First, we mentioned last week that this month's issue of the Journal of Oncology Practice (JOP) has an article, with two commentaries, on the topic …

A wonderful Sunday to you, myeloma world.

We hope that, wherever you may be today, the sun is shining as brightly as it is here at Myeloma Morning Headquarters, and that the sky is as blue.

In today's Myeloma Morning, we'll be summarizing two new myeloma-related research studies. We also have “Quickly Noted” descriptions of two additional studies. Overall, there are five items in our daily list of new multiple myeloma research, which – as always – is included at the end of our report.

Both of the studies …